Hengrui Medicine (600276.SH): HRS-8797 tablets received a notification of approval for drug clinical trials.

China Fortune Financial News APP News, Hengrui Medicine (600276.SH) announced recently that its subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for HRS-8797 tablets and will soon begin clinical trials.